Examine publishes rigorous, unbiased analysis of the latest and most important nutrition and supplementation studies each month, available to all Examine Members. Click here to learn more or log in.
Study under review: Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.
Introduction
Non-alcoholic fatty liver disease (NAFLD) impacts roughly one quarter[1] of the entire global population. NAFLD is a disease in which fat accumulates in the liver (greater than 5% of the weight of the liver) for reasons other than excessive alcohol consumption. NAFLD can be a serious issue since, as shown in Figure 1, fatty liver can ultimately cause liver damage and cirrhosis. While the condition has historically been seen primarily in adults, the rates of children with obesity in the U.S. are now roughly equal[2] to the rates of adults.

Hesperidin, a compound found in the peels of citrus fruits, depicted in Figure 2, has been investigated as a potential therapeutic option for NAFLD. Hesperidin is classified as a bioflavonoid glycoside (a type of polyphenol) and exhibits antioxidant[3] and blood lipid lowering[3] effects in humans. Additionally, previous investigations have shown that hesperidin can prevent[4] liver steatosis in rats. These data suggest that hesperidin may provide benefit for NAFLD, but until recently, this had never been tested in humans.

The present study was a randomized controlled trial studying the effects of hesperidin on hepatic steatosis as well as liver enzymes, metabolic parameters, and inflammation in individuals with NAFLD. > NAFLD affects one out of every four people. Hesperidin, a compound found in citrus peels, has been shown to have some properties that might benefit NAFLD. The present study is a double-blind, placebo-controlled trial studying the effects of hesperidin on hepatic steatosis as well as liver enzymes, metabolic parameters, and inflammation in individuals with NAFLD.
Who and what was studied?
What were the findings?
What does this study really tell us?
The big picture
Frequently Asked Questions
What should I know?
Other Articles in Issue #61 (November 2019)
-
Mini: Can exercising help alleviate primary dysmenorrhea?
We summarize the main take-aways from a recent Cochrane review exploring exercise's effects on primary dysmenorrhea.
-
Rate of weight loss and body composition: does “slow and steady” win the race?
More severe energy restriction usually leads to higher amounts of weight loss, but it could also lead to a higher proportion of muscle or bone loss. This study explored the effects of the rate of weight loss in postmenopausal women.
-
Investigating the effects of eating every other day on body composition and aging-related factors
The effects of alternate-day fasting haven't been well-explored in metabolically healthy people without obesity. This study aimed to help fill that gap.
-
Investigating dairy to improve insulin resistance
This meta-analysis suggests that dairy intake can help curb insulin resistance and shrink waistlines a little. But "dairy" is a pretty wide-ranging category...
-
Casting a wider net for marine oil’s cardiovascular benefits
We previously covered a major meta-analysis which found that marine-derived omega-3 supplementation didn't have clear cardiovascular benefits. However, three large trials have been released since then. Do they make a difference?
-
Pro-bono: protein for bone retention
When people say they want to lose weight, they usually mean losing the weight from fat. However, weight loss can also lead to bone loss. This study explored whether high-protein diets can help retain bone.
-
Mini: Nutrient supplements for mental health disorders
We summarize key takeaways from a recent umbrella review that explored how useful nutrient supplementation is for a variety of mental health issues.